New trial
Phase 1a/1b Trial of BBO-11818 in Advanced KRAS Mutant Cancers
- Trial ID
- NCT06917079 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Published in
- New in Oncology - May 7, 2025
BridgeBio Oncology is conducting a first-in-human study to assess the safety, pharmacokinetics, and preliminary antitumor activity of BBO-11818—a pan-KRAS inhibitor—in advanced, unresectable, or metastatic KRAS mutant solid tumors, either as monotherapy or in combination with agents like pembrolizumab, chemotherapy, or cetuximab.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings